0.55Open0.76Pre Close65 Volume477 Open Interest8.00Strike Price4.19KTurnover163.09%IV2.91%PremiumDec 13, 2024Expiry Date0.43Intrinsic Value100Multiplier1DDays to Expiry0.22Extrinsic Value100Contract SizeAmericanOptions Type-0.6704Delta0.4313Gamma12.62Leverage Ratio-0.1019Theta-0.0002Rho-8.46Eff Leverage0.0019Vega
Recursion Pharmaceuticals Stock Discussion
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class Cdk7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
No comment yet